tradingkey.logo
tradingkey.logo
Pesquisar

Veracyte Inc

VCYT
Adicionar à lista de desejos
38.480USD
-0.420-1.08%
Fechamento 05/15, 16:00ETCotações atrasadas em 15 min
3.07BValor de mercado
34.51P/L TTM

Mais detalhes de Veracyte Inc Empresa

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Informações de Veracyte Inc

Código da empresaVCYT
Nome da EmpresaVeracyte Inc
Data de listagemOct 30, 2013
CEOStapley (Marc A)
Número de funcionários824
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 30
Endereço6000 Shoreline Court, Suite 300
CidadeSOUTH SAN FRANCISCO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94080
Telefone16502436300
Sitehttps://www.veracyte.com/
Código da empresaVCYT
Data de listagemOct 30, 2013
CEOStapley (Marc A)

Executivos da empresa Veracyte Inc

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
151.41K
-24.55%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
53.13K
+4.05%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
41.87K
+21.64%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
32.11K
-60.63%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
32.06K
-43.95%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
29.99K
+7.18%
Mr. Evan Jones
Mr. Evan Jones
Independent Director
Independent Director
20.04K
+10.74%
Mr. Jens Holstein
Mr. Jens Holstein
Independent Director
Independent Director
17.88K
+12.04%
Mr. John Leite, Ph.D.
Mr. John Leite, Ph.D.
Global Chief Commercial Officer
Global Chief Commercial Officer
17.82K
-60.65%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Director
Independent Director
4.23K
+50.84%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Chief Executive Officer, Director
Chief Executive Officer, Director
151.41K
-24.55%
Dr. Robert S. (Rob) Epstein, M.D.
Dr. Robert S. (Rob) Epstein, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
53.13K
+4.05%
Dr. Eliav Barr, M.D.
Dr. Eliav Barr, M.D.
Independent Director
Independent Director
41.87K
+21.64%
Ms. Rebecca Chambers
Ms. Rebecca Chambers
Chief Financial Officer
Chief Financial Officer
32.11K
-60.63%
Dr. Phillip G. (Phil) Febbo, M.D.
Dr. Phillip G. (Phil) Febbo, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
32.06K
-43.95%
Ms. Muna Bhanji
Ms. Muna Bhanji
Independent Director
Independent Director
29.99K
+7.18%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de abr
Moeda: USDAtualizado em: seg, 6 de abr
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
Os dados relevantes ainda não foram divulgados pela empresa.
Por RegiãoUSD
Nome
Receita
Proporção
United States
496.60M
96.03%
International
20.55M
3.97%
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.

Distribuição de ações

Atualizado em: dom, 10 de mai
Atualizado em: dom, 10 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
14.43%
Artisan Partners Limited Partnership
6.89%
State Street Investment Management (US)
6.32%
Fidelity Management & Research Company LLC
6.12%
Vanguard Portfolio Management, LLC
5.57%
Outro
60.68%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
14.43%
Artisan Partners Limited Partnership
6.89%
State Street Investment Management (US)
6.32%
Fidelity Management & Research Company LLC
6.12%
Vanguard Portfolio Management, LLC
5.57%
Outro
60.68%
Tipos de investidores
Investidores
Proporção
Investment Advisor
64.19%
Investment Advisor/Hedge Fund
34.77%
Hedge Fund
5.42%
Research Firm
3.29%
Pension Fund
1.56%
Bank and Trust
0.60%
Individual Investor
0.57%
Holding Company
0.17%
Insurance Company
0.03%

Participação acionária institucional

Atualizado em: qua, 1 de abr
Atualizado em: qua, 1 de abr
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2026Q1
683
96.10M
120.44%
-1.89M
2025Q4
654
89.69M
113.46%
-3.72M
2025Q3
616
87.37M
110.53%
-1.45M
2025Q2
598
84.22M
107.53%
-1.90M
2025Q1
612
85.86M
109.67%
-679.43K
2024Q4
593
81.64M
104.75%
-2.62M
2024Q3
567
81.88M
106.62%
-2.30M
2024Q2
533
81.65M
106.83%
-3.86M
2024Q1
532
81.30M
103.75%
+1.22M
2023Q4
524
76.49M
104.40%
-3.87M
Ver Mais

Atividade dos acionistas

Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
11.51M
14.49%
+194.38K
+1.72%
Dec 31, 2025
Artisan Partners Limited Partnership
6.26M
7.88%
-1.11M
-15.03%
Dec 31, 2025
State Street Investment Management (US)
4.36M
5.49%
+161.24K
+3.84%
Dec 31, 2025
Fidelity Management & Research Company LLC
4.88M
6.14%
-869.86K
-15.13%
Dec 31, 2025
ARK Investment Management LLC
3.89M
4.89%
-578.23K
-12.95%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
2.80M
3.52%
-317.69K
-10.19%
Dec 31, 2025
Wellington Management Company, LLP
2.04M
2.56%
-1.34M
-39.63%
Dec 31, 2025
Geode Capital Management, L.L.C.
1.90M
2.39%
+9.43K
+0.50%
Dec 31, 2025
Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Invesco Biotechnology & Genome ETF
4.35%
ARK Genomic Revolution ETF
3.68%
First Trust NYSE Arca Biotechnology Index Fund
3.48%
Global X Genomics & Biotechnology ETF
3.13%
ROBO Global Healthcare Technology & Innovation ETF
2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
1.97%
Invesco S&P SmallCap Health Care ETF
1.74%
Franklin Genomic Advancements ETF
1.45%
ROBO Global Artificial Intelligence ETF
1.43%
ARK Innovation ETF
1.24%
Ver Mais
Invesco Biotechnology & Genome ETF
Proporção4.35%
ARK Genomic Revolution ETF
Proporção3.68%
First Trust NYSE Arca Biotechnology Index Fund
Proporção3.48%
Global X Genomics & Biotechnology ETF
Proporção3.13%
ROBO Global Healthcare Technology & Innovation ETF
Proporção2.19%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporção1.97%
Invesco S&P SmallCap Health Care ETF
Proporção1.74%
Franklin Genomic Advancements ETF
Proporção1.45%
ROBO Global Artificial Intelligence ETF
Proporção1.43%
ARK Innovation ETF
Proporção1.24%

Dividendo

Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados

Desdobramento de ações

Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
KeyAI